The T2Lyme™ Panel, a ground-breaking molecular diagnostic test created for the early diagnosis of Lyme disease, was discovered by T2 BioSystems.
The T2Lyme Panel is a molecular diagnostic test that can identify Lyme disease-causing bacteria Borrelia burgdorferi, Borrelia afzelii, and Borrelia garinii straight from a patient's blood.
It is powered by the FDA-cleared T2Dx Instrument, which was created to promote early disease diagnosis and can perform tests directly from whole blood.
There are currently no sensitive diagnostic tests for the early diagnosis of Lyme disease that have been approved by the FDA.
Humans contract Lyme disease, a bacterial infection brought on by Borrelia infections, from the bite of infected ticks. Untreated, it can result in neurological abnormalities, cognitive impairments, and persistent joint inflammation.